Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing
Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Molecular testing in advanced lung cancer is standard in guiding treatment selection. However, population-wide implementation of testing remains a challenge. We developed a knowledge translation intervention to improve understanding among diagnostic specialists about molecular testing and appropriate diagnostic sampling in lung cancer.
METHODS: Specialty-specific education programs were developed from existing literature and input from Canadian leaders in lung pathology, respirology, interventional radiology, thoracic surgery, radiation oncology, and medical oncology. The programs, including key messages, review of current data, existing guidelines, group discussion, and participant feedback, were administered at provincial and national specialty meetings. Participant knowledge was assessed before and after the intervention by using anonymous questionnaires. Molecular (EGFR) testing rates in Ontario were also evaluated before and after the intervention period.
RESULTS: Ten programs were administered to diagnostic specialists, including respirologists, pathologists, thoracic surgeons, radiologists, radiation oncologists, and medical oncologists, with completion of 255 preintervention and 219 postintervention surveys. At baseline, 30% were unsure of tissue handling methods for molecular testing, 20% chose an incorrect technique, and half were unfamiliar with how to initiate testing. After intervention, specialist knowledge improved regarding tissue handling and appropriate fixation techniques and uncertainty decreased from 30% to 2% (p < 0.001). A 12% increase (relative increase 57%) in molecular (EGFR) testing requests in Ontario was observed over the intervention period (p = 0.0032).
CONCLUSIONS: Significant knowledge gaps exist among diagnostic specialists regarding molecular testing and targeted therapy in lung cancer. This initiative significantly improved understanding of the importance and methods of successful molecular testing and correlated with increased testing rates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 13(2018), 7 vom: 15. Juli, Seite 1004-1011 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zer, Alona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 03.09.2019 Date Revised 03.09.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtho.2018.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281913366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281913366 | ||
| 003 | DE-627 | ||
| 005 | 20231225032726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtho.2018.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0939.xml |
| 035 | |a (DE-627)NLM281913366 | ||
| 035 | |a (NLM)29535011 | ||
| 035 | |a (PII)S1556-0864(18)30187-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zer, Alona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.09.2019 | ||
| 500 | |a Date Revised 03.09.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Molecular testing in advanced lung cancer is standard in guiding treatment selection. However, population-wide implementation of testing remains a challenge. We developed a knowledge translation intervention to improve understanding among diagnostic specialists about molecular testing and appropriate diagnostic sampling in lung cancer | ||
| 520 | |a METHODS: Specialty-specific education programs were developed from existing literature and input from Canadian leaders in lung pathology, respirology, interventional radiology, thoracic surgery, radiation oncology, and medical oncology. The programs, including key messages, review of current data, existing guidelines, group discussion, and participant feedback, were administered at provincial and national specialty meetings. Participant knowledge was assessed before and after the intervention by using anonymous questionnaires. Molecular (EGFR) testing rates in Ontario were also evaluated before and after the intervention period | ||
| 520 | |a RESULTS: Ten programs were administered to diagnostic specialists, including respirologists, pathologists, thoracic surgeons, radiologists, radiation oncologists, and medical oncologists, with completion of 255 preintervention and 219 postintervention surveys. At baseline, 30% were unsure of tissue handling methods for molecular testing, 20% chose an incorrect technique, and half were unfamiliar with how to initiate testing. After intervention, specialist knowledge improved regarding tissue handling and appropriate fixation techniques and uncertainty decreased from 30% to 2% (p < 0.001). A 12% increase (relative increase 57%) in molecular (EGFR) testing requests in Ontario was observed over the intervention period (p = 0.0032) | ||
| 520 | |a CONCLUSIONS: Significant knowledge gaps exist among diagnostic specialists regarding molecular testing and targeted therapy in lung cancer. This initiative significantly improved understanding of the importance and methods of successful molecular testing and correlated with increased testing rates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a EGFR | |
| 650 | 4 | |a Knowledge translation | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Quality of care | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Cutz, Jean Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Sekhon, Harman |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Sit, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Maganti, Manjula |e verfasserin |4 aut | |
| 700 | 1 | |a Sung, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Binnie, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Brade, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Tae Bong |e verfasserin |4 aut | |
| 700 | 1 | |a Kamel-Reid, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Narinder |e verfasserin |4 aut | |
| 700 | 1 | |a Tsao, Ming S |e verfasserin |4 aut | |
| 700 | 1 | |a Waddell, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a da Cunha Santos, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Milan |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Ron F |e verfasserin |4 aut | |
| 700 | 1 | |a Leighl, Natasha B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer |d 2006 |g 13(2018), 7 vom: 15. Juli, Seite 1004-1011 |w (DE-627)NLM169435504 |x 1556-1380 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g number:7 |g day:15 |g month:07 |g pages:1004-1011 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtho.2018.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2018 |e 7 |b 15 |c 07 |h 1004-1011 | ||